Particle.news
Download on the App Store
31 ARTICLES
·
2h ago

Lilly’s Oral GLP-1 Pill Hits Weight-Loss Goal in Diabetes Trial, Setting Up Global Filings

Lilly says the non‑peptide, once‑daily pill is taken without fasting or water restrictions, a profile that could broaden access through simpler manufacturing.

Eli Lilly Biotechnology Center is shown in San Diego, California, U.S. March 1, 2023. REUTERS/Mike Blake/File Photo
Image
Image

Overview

  • In the 72‑week ATTAIN‑2 Phase 3 study of 1,600+ adults with overweight or obesity and type 2 diabetes, orforglipron 36 mg produced a mean 10.5% weight reduction versus 2.2% with placebo.
  • Across doses, A1C fell by an average of 1.3% to 1.8% from a baseline of 8.1%, and 75% of participants on 36 mg reached an A1C of 6.5% or lower.
  • Dose response was observed, with 50.1% of patients on 36 mg achieving at least 10% weight loss and 28.4% reaching 15% or more.
  • Gastrointestinal events were the most common side effects (nausea 36.4%, vomiting 23.1%, diarrhea 27.4% at 36 mg), and about 10.6% on the highest dose discontinued due to adverse events.
  • Eli Lilly says it now has the full clinical data package to initiate global regulatory submissions, positioning the pill against rival oral GLP‑1 efforts and highlighting its lack of dietary restrictions.